Advancing Theragnostics in Prostate Cancer

2.5 hrs

Total Session Length

4

Specialist Presentations

4

Live Q&A Sessions

15 min

Attendance Registration

Follow the sequence of the sessions, guest keynotes, and dedicated Q&A slots throughout the evening program.

Welcome & Registration

Dr. Fawzia Al-Arfi

Attendee check-in, credential verification, and introductory symposium welcome.

Expert address on precision oncology frameworks and clinical case studies.

Dr. Mohammed Hashlan

Q&A Session

Keynote presentation on clinical protocols and evidence-based patient evaluations.

Direct attendee question segment with Dr. Al-Arfi.

Dr. Ahmed Al-Zahrani

Q&A Session

Closing lecture on advanced theragnostic implementation in prostate cancer.

Interactive discussion and audience questions addressing Dr. Hashlan's talk.

Q&A Session

Dr. Emad Tashkandi

Final session panel exchange and attendee inquiries.

Featured presentation exploring PSMA radioligand therapy integration.

Closing Remarks & Registration Wrap-up

Q&A Session

Open floor consultation with Dr. Tashkandi on clinical findings and practice.

Concluding symposium summary, attendance certificates, and closing steps.

Distinguished Specialists

Gain insights from leading voices in PSMA theragnostics, nuclear medicine, and urological oncology. Each brings unique clinical efficacy to the discussion.

Oncologist

Nuclear Medicine Physician

Radiopharmaceutical Researcher

Urological Surgeon

Specializing in advanced prostate cancer treatments and clinical trial design.

Expert in radiopharmaceutical imaging and diagnostic scan interpretation.

Driving innovation in novel PSMA ligand development and application.

Focusing on surgical interventions and integrated theragnostic approaches.

Ensure your participation in this essential clinical symposium. Complete your registration to access all sessions and materials.